Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Non-resectable Interventions: Procedure: HAIC; Drug: Lenvatinib plus cadonilimab Sponsors: Tongji Hospital; Geneplus-Beijing Co. Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Research